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Vesicular delivery systems have gainedmuch attention as phar-
maceutical entities since their discovery. Niosomes occupy the
general structure of bilayer vesicles, having a hydrophilic core
shielded from one or multiple hydrophobic lipid bilayer. This
unique structure enables them to both accommodate oil-
soluble compounds as well as to encapsulate water-soluble drugs
[1]. The anticancer effects of tocotrienol were first discovered
in the early 1990s when Nesaretnam et al. reported that palm
oil stripped of vitamin E-promoted tumorigenesis in rats [2]. In
2006, the first clinical trial of tocotrienol in breast cancer was
conducted. The risk of mortality due to breast cancer was 60%
lower when tocotrienol rich fraction (TRF) was given together
with tamoxifen. Five-year breast cancer specific survival and
disease free survival were also slightly improved with adju-
vant tocotrienol therapy [3]. In this study, we aim to prepare and
optimize a formulation of niosomes loaded with tocotrienol rich
fraction (TRF) for potential delivery to breast cancer.
Niosomes loadedwithTRFwere prepared using 146.4mg span
60, 131.4 mg cholesterol and 102.9 mgTPGS.TRF of varying con-
centrations (10 mg/mL–30 mg/mL) were added into the mixture
and stirred at 450 rpm for 1 h at 90 °C. After which the samples
were subjected to probe sonication at 75% of the maximum ca-
pacity using QSonica Q125 probe sonicator for 6 minutes. The
samples were then ultracentrifuged (Beckman Coulter Optima™
L-100 XP) at 40,000 rpm for 6 hours at 4 °C to remove free
unboundmaterials.The niosomes were then collected from the
pellet and resuspended in PBS. The niosomes were freeze-
dried for 3 days and resuspended in PBS before use. The size
of the niosomes was measured using Nano-Zetasizer (Malvern
Instruments, UK). TRF loading were determined by HPLC. Dif-
ferent concentrations of TRF yield niosomes with slightly
different sizes. The sizes are in the range of 300–400 nm. The
% ofTRF loaded onto the niosomes also differ, in a general trend
of increasing amount loaded with increasing concentration of
TRF used. Based on the results on size andTRF loading, niosomes
prepared with TRF loading of 25 mg/mL appeared to be the
optimal preparation with average size of 298.25 nm and 11.96%
TRF loading.
This preliminary study showed that TRF can be success-
fully loaded onto the niosomes, and the optimal preparation
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was selected based on size and amount of loaded TRF. Further
studies will be carried out to determine the morphology of the
niosomes using scanning electron microscope, as well as to
determine the TRF release from the niosomes.
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Fig. 1 Graphs showing (a) size and (b) percentage TRF loading
of niosomes prepared with varying concentrations of TRF.
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